PT  - JOURNAL ARTICLE
AU  - PARK, HYE MI
AU  - HONG, SEUNG HO
AU  - KIM, JONG WOO
AU  - OH, DOYEUN
AU  - HWANG, SEONG GYU
AU  - AN, HEE JUNG
AU  - KIM, NAM KEUN
TI  - Gender-specific Association of the <em>VEGF</em> -2578C>A Polymorphism in Korean Patients with Colon Cancer
DP  - 2007 Jul 01
TA  - Anticancer Research
PG  - 2535--2539
VI  - 27
IP  - 4B
4099  - http://ar.iiarjournals.org/content/27/4B/2535.short
4100  - http://ar.iiarjournals.org/content/27/4B/2535.full
SO  - Anticancer Res2007 Jul 01; 27
AB  - Background: Angiogenesis is involved in the development of cancer, promoting tumor growth, invasiveness and metastasis. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor. The present case control study was carried out, to determine whether there is an association between the VEGF -2578C>A polymorphism and colon cancer. Patients and Methods: DNA samples taken from 246 patients with colon cancer and 203 healthy controls were amplified by polymerase chain reaction for VEGF -2578C>A polymorphism. Results: Genotype frequencies of the VEGF -2578C>A polymorphism were not significantly different between patient and control groups. However, when the data were stratified by gender, the frequency of the -2578CA+AA (A allele-bearing) genotype was marginally significant different with protective effect for colon cancer in women (odds ratio, OR, 0.60; 95% confidence interval, CI, 0.36-0.99; p=0.056). The -2578CA+AA genotype was also associated with reduced risk in patients with proximal colon cancer (OR, 0.55; 95% CI, 0.31-0.97; p=0.049). This association also remained in women with proximal colon cancer. Conclusion: Although the VEGF -2578C>A polymorphism had no influence on susceptibility to colon cancer, some genotypes showed a significant difference between the case and control groups when the data were stratified by gender and the original location of tumor, suggesting that the VEGF -2578C>A polymorphism, at least in Koreans, is a genetic determinant of colon cancer risk. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved